Repression of the stress granule protein G3BP2 inhibits immune checkpoint molecule PD‐L1
Author(s) -
Zhang Yanhong,
Yue Changli,
Krichevsky Anna M.,
Garkavtsev Igor
Publication year - 2025
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1002/1878-0261.12915
Subject(s) - stress granule , immune system , cancer research , immune checkpoint , cd8 , pd l1 , cancer immunotherapy , breast cancer , immunotherapy , biology , cancer cell , cytotoxic t cell , microbiology and biotechnology , cancer , immunology , messenger rna , biochemistry , genetics , gene , translation (biology) , in vitro
Mounting evidence suggests that cancer stemness and immunosuppression are related, but the underlying mechanisms behind these are not clear. We previously reported that the stress granule‐associated protein G3BP2 is involved in the regulation of tumor‐initiating (stem) cells. In this study, we show that this protein also upregulates the immune checkpoint molecule PD‐L1 under conditions of stress in breast and glioblastoma cancer cells, revealing a previously unknown connection between stemness programs, stress responses, and immune checkpoint control. We also identified a significant correlation between G3BP2 and PD‐L1 co‐expression in tumor tissues from cancer patients. To assess the targetability of G3BP2, we employed a small molecule (C108) that binds G3BP2 and interferes with the stress response. Tumors treated with C108 had increased CD8 T‐cell proliferation and infiltration. Moreover, treatment of breast tumor‐bearing mice with C108 resulted in a significant survival benefit and long‐term cures. Cancer cells treated with C108 or cancer cells with genetically repressed G3BP2 had decreased PD‐L1 expression due to enhanced mRNA degradation. Our study provides a compelling mechanism linking stress granule formation and immune checkpoint program of cancer, suggesting this link may provide new opportunities for improving anticancer immunotherapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom